报价延迟最少15分钟:2026/04/15 11:05 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
81.805 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-9.73/-13.15
|
|
企业价值
2.40B
|
| 资产负债 |
|
每股账面净值
3.13
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
55.23M
|
|
每股收益
3.08
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255. |
